Funding & Grants
Grants
Shapes
Smart and healthy ageing through people engaging in supportive systems
Funder: H2020 – Trusted digital solutions and cybersecurity in health and care
Partners: 36 partners from across Europe
i-Simpathy
Implementing Stimulating Innovation in the Management of Polypharmacy and Adherence in the Elderly
Funder: Interreg
Partners: 3 partners from Northern Ireland, Ireland and Scotland
Past Grants
Pathways to Impact
3D Printed, Stand-alone, Colourimetric Indicator Strip (3DCIS) for Non-Invasive, On-demand Chronic Wound Monitoring
Funder: EPSRC
Partners: Queens University Belfast
Simpathy
Stimulating Innovation Management of Polypharmacy and Adherence in The Elderly
Funder: European Union’s Health Programme (2014-2020)
Commercial Funding
Accelerate Diagnostics
Evaluation of the Accelerate device designed for rapid antimicrobial susceptibility testing
Sub Epidermal Moisture (SEM) ScannerTM
Evaluation of a SEM Scanner Device for early identification of pressure-induced tissue damage
Northern Pharmacies Ltd.
Point of Care Testing for Cough, Cold and Flu
Sunovian
An audit of interventions made over the previous year in patients with Serious Mental Illness (Schizophrenia, Schizoaffective or Bipolar) treated with Antipsychotics
Virtual heart failure clinics in SHSCT
This project involved a partnership between the commercial partner, MOIC and SHSCT. Funding was obtained from the commercial partner to undertake work with the cardiology team and primary care colleagues to establish, deliver and evaluate virtual heart failure clinics (HFVC).
Cardiometabolic Pharmacist in the Western Health and Social Care Trust (WHSCT)
A pilot project involving the introduction of a cardiometabolic pharmacy service in the WHSCT was completed with funding support from the commercial partner. This project aimed to improve outcomes for patients with or at risk of cardiometabolic disease (CMD) by increasing adherence to medicines that prevent/delay disease progression and identifying patients suitable for sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in line with updated clinical guidelines.